StockNews.com initiated coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report released on Wednesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Nabriva Therapeutics Price Performance
The company has a debt-to-equity ratio of 0.12, a current ratio of 0.85 and a quick ratio of 0.52. The company’s 50-day moving average price is $0.14. The company has a market cap of $45.46 million, a P/E ratio of -0.07 and a beta of 1.53. Nabriva Therapeutics has a 12-month low of $1.22 and a 12-month high of $8.45.
Nabriva Therapeutics Company Profile
See Also
- Five stocks we like better than Nabriva Therapeutics
- Do ETFs Pay Dividends? What You Need to Know
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Profitably Trade Stocks at 52-Week Highs
- MarketBeat Week in Review – 8/5 – 8/9
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.